Biotel Inc. announced results for its first quarter ended September 30, 2009 with net earnings of $128,000, or $0.04 per diluted share, on revenues of $3,263,000. This compares to net earnings of $328,000, or $0.11 per diluted share, on revenues of $3,168,000 for the first quarter of last year. [More]

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced today the final results for its previously announced cash tender offer (the "Tender Offer") to purchase any and all of its 5.125% Senior Notes due 2010 and any and all of its 7.50% Senior Notes due 2011 (collectively, the "Notes"). [More]

RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, reported today company-wide net sales of $6.49 million for the quarter ended September 30, 2009, compared to net sales of $9.93 million for the same quarter last year. [More]

In a move to consolidate corporate brand identity, MedeAnalytics, a leading provider of healthcare performance management solutions, today announced that the name of its London-based U.K. subsidiary Mede International Ltd. has been changed to MedeAnalytics International Ltd., with MedeAnalytics to serve as its brand. [More]

CombinatoRx, Incorporated and Neuromed Pharmaceuticals Inc., a privately-held biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued Neuromed a letter extending its review of the New Drug Application (NDA) for the product candidate Exalgo™ (hydromorphone HCl) extended-release tablets by three months. [More]

BD today announced the completion of its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms. [More]

“It is extremely satisfying that the major development efforts during recent years are now beginning to pay off. In November our new product for Philips started generating revenues and we anticipate that the total revenue contribution from this and other new products will exceed SEK 10 M already in the fourth quarter,” says Johan Löf, President of RaySearch. [More]

Cell Therapeutics, Inc. announced today that the Ninth Circuit Court of Appeals reversed a U.S. District Court order and ruled that CTI should be allowed to pursue all of its claims against The Lash Group, sending the case back to the District Court for trial. CTI filed a complaint against The Lash Group, CTI's former third-party reimbursement consultant for CTI's product TRISENOX, in 2007 seeking $22.8 million in damages for expenses already incurred related to the investigation, defense and a settlement of claims by the U.S. government concerning Medicare reimbursement for TRISENOX and other business losses. [More]

Karolinska Development AB today announced that the European Investment Fund (EIF) has entered into a co-investment agreement with the company. The co-investment fund will be managed by Karolinska Development and used to invest in the company's portfolio of early-stage pharmaceutical and medical technology companies. [More]

Pharmaceutical companies face a fundamental decision about the best way to sell their products. Even if they could find a way to make the current sales model work, pharma companies still face sky-high commercial costs. So, the question is, should pharma companies stick with their traditional sales approach or blow it up and try something new? [More]

A recent Reuters article reported that America's pharmaceutical research and biotechnology companies don't expect an industry increase as a result of broader insurance coverage proposed in health care reform. [More]

National Health Investors, Inc. announced today it has closed a $28.25 million purchase/leaseback transaction with Bickford Senior Living and its affiliates involving four assisted living facilities in Michigan and one in Illinois. The assisted living communities are two to three years old totaling 216 units and attract 100% private payment for services. [More]

Emergency Medical Services Corporation today announced that certain of its equity holders, primarily affiliates of Onex Corporation, have priced a public secondary offering of 8,000,000 shares (increased from 6,000,000) of class A common stock at $48.31 per share. [More]

BioCryst Pharmaceuticals, Inc. today announced the pricing of a public offering of 5,000,000 shares of its common stock at $9.75 per share, resulting in gross proceeds of $48.75 million. [More]

Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced a strategic partnership between the company's contract research organization, Caliper Discovery Alliances & Services (CDAS), and Prestwick Chemical (Strasbourg, France) to provide customized outsourced medicinal chemistry and in vitro and in vivo preclinical biology programs for drug discovery research. [More]